ATAI
ATAI Life Sciences is a clinical-stage biopharmaceutical company aiming to revolutionise current solutions to mental health care. The company is best known for exploring the use of psychedelics, such as the chemical compound psilocybin found in ‘magic mushrooms’, in clinical treatments for mental illness.
Their portfolio companies include COMPASS Pathways, Perception Neuroscience, DemeRx, Innoplexus, GABA Therapeutics, EntheogeniX Biosciences, Neuronasal.
QC·Ventures is a proud investor from the Series A round in 2018 to the highly successful IPO in June 2021.